501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro
H. Liu, P. Wei, Q. Zhang, Z. Chen, K. Aviszus, W. Downing, S. Peterson, L. Reynoso, G. Downey, S. Frankel, J. Kappler, P. Marrack, G. Zhang
The paper shows that the 501Y.V2 and 501Y.V3 SARS-CoV-2 variants have mutations that reduce binding to the antibody Bamlanivimab.
bioRxiv · Feb 16, 2021Biochemistry